Atossa Genetics (ATOS) Competitors $0.78 -0.01 (-0.74%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.79 +0.01 (+1.01%) As of 08/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. MBX, ATYR, CMPS, KMDA, UPXI, RGNX, CMPX, PVLA, ERAS, and TECXShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include MBX Biosciences (MBX), aTyr Pharma (ATYR), COMPASS Pathways (CMPS), Kamada (KMDA), Upexi (UPXI), REGENXBIO (RGNX), Compass Therapeutics (CMPX), Palvella Therapeutics (PVLA), Erasca (ERAS), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors MBX Biosciences aTyr Pharma COMPASS Pathways Kamada Upexi REGENXBIO Compass Therapeutics Palvella Therapeutics Erasca Tectonic Therapeutic Atossa Genetics (NASDAQ:ATOS) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Do institutionals and insiders believe in ATOS or MBX? 12.7% of Atossa Genetics shares are owned by institutional investors. 7.6% of Atossa Genetics shares are owned by company insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ATOS or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -40.28% -37.10% MBX Biosciences N/A N/A N/A Which has higher earnings & valuation, ATOS or MBX? Atossa Genetics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$25.50M-$0.21-3.71MBX BiosciencesN/AN/AN/A-$4.54-2.91 Does the media favor ATOS or MBX? In the previous week, Atossa Genetics had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 6 mentions for Atossa Genetics and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.32 beat Atossa Genetics' score of -0.02 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ATOS or MBX? Atossa Genetics currently has a consensus target price of $6.17, indicating a potential upside of 690.50%. MBX Biosciences has a consensus target price of $37.63, indicating a potential upside of 184.82%. Given Atossa Genetics' stronger consensus rating and higher possible upside, research analysts plainly believe Atossa Genetics is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtossa Genetics and MBX Biosciences tied by winning 6 of the 12 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.52M$7.00B$5.61B$9.84BDividend YieldN/A1.30%4.61%4.07%P/E Ratio-3.3925.4830.2925.74Price / SalesN/A73.48463.41115.83Price / CashN/A21.9738.2159.48Price / Book1.735.388.826.15Net Income-$25.50M$176.29M$3.25B$265.06M7 Day Performance-0.88%3.21%3.70%2.60%1 Month Performance-14.72%1.49%5.84%2.83%1 Year Performance-39.05%10.20%29.92%25.58% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics2.7119 of 5 stars$0.78-0.7%$6.17+690.5%-37.1%$101.52MN/A-3.398Earnings ReportMBXMBX Biosciences2.5583 of 5 stars$12.54-8.8%$37.57+199.6%N/A$419.14MN/A0.0036News CoverageATYRaTyr Pharma2.184 of 5 stars$5.02+6.8%$20.20+302.4%+169.7%$418.32M$230K0.0053Earnings ReportShort Interest ↑Analyst RevisionCMPSCOMPASS Pathways2.5957 of 5 stars$4.60+6.0%$16.29+254.0%-38.3%$416.39MN/A0.00120KMDAKamada4.5869 of 5 stars$7.19-0.4%$13.00+80.8%+37.0%$415.19M$160.95M24.79360News CoverageEarnings ReportShort Interest ↓UPXIUpexi2.9932 of 5 stars$5.02+9.1%$15.50+208.8%+94.2%$411.06M$26M0.00130Analyst UpgradeShort Interest ↑Gap DownRGNXREGENXBIO4.241 of 5 stars$8.33+1.7%$31.63+279.7%-24.1%$410.81M$83.33M-2.68370Gap DownCMPXCompass Therapeutics2.7315 of 5 stars$2.85-3.4%$12.67+344.4%+158.8%$407.93M$850K0.0020Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionPVLAPalvella Therapeutics1.7307 of 5 stars$37.20+1.8%$52.22+40.4%N/A$404.08M$42.81M0.00N/ANews CoverageERASErasca2.4372 of 5 stars$1.40+0.7%$4.57+226.5%-39.4%$393.77MN/A0.00120News CoverageEarnings ReportTECXTectonic Therapeutic2.2606 of 5 stars$21.16+2.1%$80.33+279.6%+52.4%$387.08MN/A0.00120 Related Companies and Tools Related Companies MBX Alternatives ATYR Alternatives CMPS Alternatives KMDA Alternatives UPXI Alternatives RGNX Alternatives CMPX Alternatives PVLA Alternatives ERAS Alternatives TECX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access